@article{03e453b5f0c244cda8cd612843966482,
title = "Prescriber Attitudes, Experiences, and Proclivities Toward Digital Medicine and How They Influence Adoption of Digital Medicine Platforms",
abstract = "Background: Psychiatric prescribers (prescribers) typically assess medication adherence by patient or caregiver self-report. Despite likely clinical benefit of a new digital medicine technology, the role of specific prescriber attitudes, behaviors, and experiences in the likelihood of adoption is unclear. Objective: To identify prescriber characteristics that may affect adoption of the ingestible event marker (IEM) platform. Design: A survey of prescribers treating seriously mentally ill patients was conducted. Factor analysis was performed on 11 items representing prescriber characteristics believed to be related to endorsement of the IEM platform. Four factors were extracted. Regression analysis was used to test the strength of the relationships between the factors and likelihood of adoption of the IEM platform. Results: A total of 131 prescribers completed the survey. Most (84%) agreed that visits allow enough time to monitor adherence. Factor analysis revealed four underlying dimensions: 1) perspectives on the value of adherence; 2) concerns about measuring adherence; 3) views toward digital health technologies; and 4) views on payer role/reimbursement. Factors 1 and 3 were related to gender, the belief that computerization benefits prescribers, the presence of office support staff, and the belief that new digital medicine (DM) technology will be cost prohibitive. Willingness to adopt the IEM platform was related to gender (p < 0.05) and perspectives on the value of adherence (p < 0.05), with those scoring higher on that measure also being more likely to adopt. Conclusion: Psychiatric prescribers are concerned about medication adherence, perceive current monitoring tools to be problematic, and are open to using digital technologies to improve accuracy of adherence assessment. Relationships among prescriber characteristics, beliefs, and experiences should be considered when developing educational materials, particularly when the goal is to encourage adoption and use of the IEM platform.",
keywords = "antipsychotic, digital health technologies, gender differences, medication adherence, mental illness, personalized medicine",
author = "Charles Ruetsch and Tigwa Davis and Liberman, {Joshua N.} and Velligan, {Dawn I.} and Delbert Robinson and Chris Jaeger and William Carpenter and Felica Forma",
note = "Funding Information: Dr Charles Ruetsch reports grants, personal fees from Otsuka America, during the conduct of the study; personal fees from Pear Therapeutics for consulting on digital therapeutics, involved in HEOR Project in the area of major depressive disorder for Janssen Scientific Affairs and Acadia Pharmaceuticals, personal fees from Atentiv for consulting on digital therapeutic HEOR evidence generation plan, outside the submitted work. Dr Tigwa Davis reports personal fees from Otsuka America Pharmaceutical, Inc., during the conduct of the study. Dr Joshua N Liberman reports funding from Otsuka Pharmaceutical Development & Commercialization, Inc. for his affiliation, Health Analytics LLC research services. Dr Dawn I Velligan reports non-financial support for consultant speaker{\textquoteright}s bureau and manuscript preparation from Otsuka, during the conduct of the study; advisory board for Lindra, Alkermes, Janssen, and Otsuka, outside the submitted work. Dr Delbert Robinson reports personal fees from Health Analytics, during the conduct of the study; personal fees and/or grants from Otsuka and Lundbeck, outside the submitted work. Dr William Carpenter reports personal fees from Boehringer Ingelheim for data management and safety board, personal fees from Tiva for presentation, personal fees from Lundbeck as an advisor, outside the submitted work. Felicia Forma is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. The authors report no other conflicts of interest in this work. Funding Information: Financial support for this study was provided entirely by a contract with Otsuka Pharmaceutical Development & Commercialization, Inc. The funding agreement ensured the authors{\textquoteright} independence in designing the study, interpreting the data, writing, and publishing the report. Publisher Copyright: {\textcopyright} 2021 Ruetsch et al.",
year = "2021",
doi = "10.2147/NDT.S318344",
language = "English (US)",
volume = "17",
pages = "3715--3726",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
}